PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
Initiative will create one of the world’s largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel precision medicine
Excerpt from the Press Release:
PLEASANTON, Calif., Feb. 4, 2026 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that PharosAI, a research consortium uniting four leading UK institutions, will use the 10x Genomics Xenium spatial platform to build one of the world’s most comprehensive multimodal cancer datasets and pair them with advanced AI models and analytical capabilities. Backed by £18.9 million from the UK Government’s Research Ventures Catalyst and additional support from charities and industry partners, PharosAI will deliver a nexus of large-scale, AI-ready datasets, computational models and analytical tools to accelerate earlier diagnosis, enable precision therapies and speed the discovery of new treatments.
PharosAI brings together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ NHS Foundation Trust and Barts Health NHS Trust in a joint venture that combines clinical expertise, academic leadership and advanced technologies. By leveraging 10x Genomics’ Xenium spatial platform, PharosAI intends to transform decades of archived NHS cancer samples into high-resolution, multimodal datasets that could be used by researchers, clinicians and innovators worldwide to power AI models for diagnosis and drug discovery to improve patient care and outcomes.
“AI has the potential to transform cancer care, but its progress has been held back by fragmented and inaccessible data,” said Professor Anita Grigoriadis, CEO of PharosAI and Professor of Molecular and Digital Pathology at King’s College London. “PharosAI changes that – creating rich, multimodal datasets and pairing them with cutting-edge AI models and analytical tools, powered by 10x Genomics’ advanced spatial technologies to enable earlier diagnoses, more targeted therapies and better outcomes for patients. By uniting universities, NHS Trusts, charities and industry, we are building an ecosystem for breakthrough discoveries.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?